116
RUSSIA - FRANCE
I
n2017,Serviercelebratedthetwenty-
fifth anniversary of its arrival in
Russia and the tenth anniversary of
its ‘Servier RUS’ production site, which
is located in the new part of Moscow.
Canyou tell usabout howyouset up the
subsidiary in Russia and how it has
developed?
The Group operates in 148 countries,
has 78% of its revenues (originator
brand drugs and generics), and 93% of
the revenues of the originator brand
activity come from outside France. We
have never stopped developing since we
arrived in the Russian market in the
early 1990s. Today, the Servier Group
employs nearly 2,000 people in Russia.
After our representative office opened
in 1992, the second major step in our
market entry was the creation of our
International Therapeutic Research
Centre in 1999. Its main mission is to
support the clinical development of our
drugs, especially by using the contribu-
tions of Russian centres of expertise in
our international clinical trials, which
are essential for registering our drugs.
Servier was also one of the first labora-
tories to set up a manufacturing site in
Russia, called Servier RUS. Since 2009,
we have grown from a packaging activi-
ty to total pharmaceutical production.
Today, our company is among the five
top international pharmaceutical cor-
porations in Russia. Nearly all (more
than 96%) of the needs for Servier
drugs in the Russian market are
covered by this site.
We are strengthening our presence in
the region by capitalizing on the exper-
tise of our local team and the experien-
ce we have acquired. In 2016, we signed
a cooperation agreement with the
Republic of Tatarstan for developing a
public health programme. In May 2018,
we participated in the Saint-Petersburg
International Economic Forum. This
was an opportunity to improve our visi-
bility and once more show the Russian
government that we are not only a relia-
ble strategic partner but also a solid
investor. This event also led to the
signature of an agreement with the
Government of Saint Petersburg to
foster the prevention and treatment of
non-communicable chronic diseases
(cardiovascular diseases & diabetes).
Servier has become one of the leading
investors in Russia for the entire drug
productioncycle.What is the roleof the
Russian subsidiary in the Group’s
development?
To keep our position as the leader in
this market we endeavour to align our
investment strategy with Russia’s
economic priorities, in which the
pharmaceutical industry plays a role.
The Russian government has the goal
of making the sector more and more
competitive and reducing dependence
on imports.
We are also contributing our expertise
to developing the country’s exports, in
The Servier Group is a leader in prescription drugs and a major player in clinical
research and is contributing to the improvement of the Russian health system.
Jérôme GAVET,
Managing Director of Servier Russia and Eurasian Economic Union
©DR
‘Russia is a highly strategic market
for the Group’s international development’
©DR
